Published in J Acquir Immune Defic Syndr on November 01, 2008
Late entry to HIV care among Latinos compared with non-Latinos in a southeastern US cohort. Clin Infect Dis (2011) 2.20
Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer (2009) 1.95
The problem of late ART initiation in Sub-Saharan Africa: a transient aspect of scale-up or a long-term phenomenon? J Health Care Poor Underserved (2013) 1.75
The economic burden of late entry into medical care for patients with HIV infection. Med Care (2010) 1.69
Routine HIV screening in France: clinical impact and cost-effectiveness. PLoS One (2010) 1.46
Late presenters among persons with a new HIV diagnosis in Italy, 2010-2011. BMC Public Health (2013) 1.23
Factors associated with presentation to care with advanced HIV disease in Brussels and Northern France: 1997-2007. BMC Infect Dis (2011) 1.18
Advanced disease at enrollment in HIV care in four sub-Saharan African countries: change from 2006 to 2011 and multilevel predictors in 2011. AIDS (2014) 1.17
Missed opportunities for HIV testing in newly-HIV-diagnosed patients, a cross sectional study. BMC Infect Dis (2013) 1.14
Clinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapy. J Infect Dis (2010) 1.11
CD4 Cell Counts at HIV Diagnosis among HIV Outpatient Study Participants, 2000-2009. AIDS Res Treat (2011) 1.00
Scaling up antiretroviral treatment services in Karnataka, India: impact on CD4 counts of HIV-infected people. PLoS One (2013) 0.99
Older HIV-infected individuals present late and have a higher mortality: Brighton, UK cohort study. BMC Public Health (2013) 0.97
Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy. J Acquir Immune Defic Syndr (2016) 0.95
HIV risk behaviors and sociodemographic features of HIV-infected Latinos residing in a new Latino settlement area in the Southeastern United States. AIDS Care (2013) 0.95
Comparing Measures of Late HIV Diagnosis in Washington State. AIDS Res Treat (2011) 0.89
The potential impact of routine testing of individuals with HIV indicator diseases in order to prevent late HIV diagnosis. BMC Infect Dis (2013) 0.88
Time trends and correlates of late presentation for HIV care in Northern Greece during the decade 2000 to 2010. J Int AIDS Soc (2012) 0.87
Gender difference in advanced HIV disease and late presentation according to European consensus definitions. Sci Rep (2015) 0.84
Early diagnosis and treatment of HIV infection: magnitude of benefit on short-term mortality is greatest in older adults. Age Ageing (2013) 0.83
Reduced Central Memory CD4+ T Cells and Increased T-Cell Activation Characterise Treatment-Naive Patients Newly Diagnosed at Late Stage of HIV Infection. AIDS Res Treat (2011) 0.81
Late Presentation into Care of HIV Disease and Its Associated Factors in Asia: Results of TAHOD. AIDS Res Hum Retroviruses (2015) 0.81
The risk of late or advanced presentation of HIV infected patients is still high, associated factors evolve but impact on overall mortality is vanishing over calendar years: results from the Italian MASTER Cohort. BMC Public Health (2016) 0.77
Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA (2008) 6.07
Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet (2006) 5.19
Short-course antiretroviral therapy in primary HIV infection. N Engl J Med (2013) 4.82
Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis (2004) 4.26
Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet (2003) 3.84
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ (2011) 3.72
Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis (2012) 3.71
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet (2004) 3.59
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nat Immunol (2011) 3.48
Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS (2006) 3.23
Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med (2012) 3.12
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol (2011) 2.80
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ (2005) 2.51
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS (2009) 2.50
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS (2007) 2.47
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS (2005) 2.45
Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines. Clin Infect Dis (2011) 2.30
Response to combination antiretroviral therapy: variation by age. AIDS (2008) 2.28
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS (2014) 2.27
Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med (2002) 2.20
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol (2010) 2.06
Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis (2008) 2.06
Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis (2009) 2.04
Coronary aging in HIV-infected patients. Clin Infect Dis (2009) 2.02
Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis. Clin Infect Dis (2009) 1.95
Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol (2008) 1.90
Stable changes in CD4+ T lymphocyte miRNA expression after exposure to HIV-1. Blood (2012) 1.89
Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. J Antimicrob Chemother (2007) 1.89
One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence (2010) 1.84
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. AIDS (2009) 1.81
Region of difference 1 antigen-specific CD4+ memory T cells correlate with a favorable outcome of tuberculosis. J Infect Dis (2006) 1.80
Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol (2002) 1.79
Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. AIDS (2005) 1.75
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS (2007) 1.73
Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. J Clin Epidemiol (2005) 1.72
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect Dis (2011) 1.68
Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies. PLoS Med (2010) 1.65
The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS (2011) 1.65
Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS (2010) 1.57
Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET-Study. PLoS One (2008) 1.56
Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS (2005) 1.55
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? Clin Infect Dis (2010) 1.54
Kaposi's sarcoma in transplant and HIV-infected patients: an epidemiologic study in Italy and France. Transplantation (2005) 1.52
The Vα14 invariant natural killer T cell TCR forces microbial glycolipids and CD1d into a conserved binding mode. J Exp Med (2010) 1.50
Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clin Infect Dis (2011) 1.50
Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest (2009) 1.49
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses (2002) 1.45
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014. New Microbiol (2015) 1.45
Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. Respir Res (2007) 1.45
Temporal trends in postseroconversion CD4 cell count and HIV load: the Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002. J Infect Dis (2007) 1.44
Galactose-modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis. EMBO J (2011) 1.43
Upregulation of interferon-induced genes in infants with virus-associated acute bronchiolitis. Exp Biol Med (Maywood) (2007) 1.42
Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis (2008) 1.40
Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer (2007) 1.40
Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy. Clin Infect Dis (2004) 1.40
Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis (2012) 1.39
Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. AIDS (2004) 1.38
The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS (2006) 1.37
Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol (2008) 1.35
Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer. Eur J Cancer (2008) 1.33
Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART. J Med Virol (2005) 1.32
Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. J Natl Cancer Inst (2010) 1.31
Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome. Antivir Ther (2011) 1.30
Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor FcɛRI. Nat Struct Mol Biol (2011) 1.29
Selected RD1 peptides for active tuberculosis diagnosis: comparison of a gamma interferon whole-blood enzyme-linked immunosorbent assay and an enzyme-linked immunospot assay. Clin Diagn Lab Immunol (2005) 1.29
Extensively drug-resistant tuberculosis, Italy and Germany. Emerg Infect Dis (2007) 1.29
Increased mitochondrial DNA content in peripheral blood lymphocytes from HIV-infected patients with lipodystrophy. Antivir Ther (2003) 1.26
Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis (2014) 1.25
The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol (2003) 1.23
Physician estimates of adherence and the patient-physician relationship as a setting to improve adherence to antiretroviral therapy. J Acquir Immune Defic Syndr (2002) 1.23
Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS (2008) 1.23
Definition and epidemiology of late presentation in Europe. Antivir Ther (2010) 1.23
Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med (2014) 1.22
Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences. J Acquir Immune Defic Syndr (2006) 1.22
Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS One (2012) 1.22
Cutting edge: structural basis for the recognition of β-linked glycolipid antigens by invariant NKT cells. J Immunol (2011) 1.20
The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am J Gastroenterol (2007) 1.20
Primary HIV infection: to treat or not to treat? Curr Opin Infect Dis (2008) 1.18
Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons? PLoS One (2010) 1.18
Cytotoxic granule release dominates gag-specific CD4+ T-cell response in different phases of HIV infection. AIDS (2010) 1.16
Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr (2005) 1.14
CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era. AIDS (2010) 1.14
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One (2010) 1.13
Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. PLoS One (2012) 1.13